Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

New England Journal of Medicine

Volumn 349, Issue 8, 2003, Pages 743-752

  Löwenberg, Bob ^a   Van Putten, Wim ^a   Theobald, Matthias ^b   Gmür, Jurg ^c   Verdonck, Leo ^d   Sonneveld, Pieter ^a   Fey, Martin ^e   Schouten, Harry ^f   De Greef, Georgine ^a   Ferrant, Augustin ^g   Kovacsovics, Tibor ^h   Gratwohl, Alois ⁱ   Daenen, Simon ^j   Huijgens, Peter ^k   Boogaerts, Marc ^l  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c KLINIK IM PARK   (Switzerland)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF BERN   (Switzerland)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; STEM CELL MOBILIZATION; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0042967809     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa025406     Document Type: Article

References (32)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341:1051-62. [Erratum, N Engl J Med 1999; 341:1484.]
2. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988;2:810-3.
3. Lista P, Porcu P, Avanzi GC, Pegoraro L. Interleukin 3 enhances the cytotoxic activity of 1-β-D-arabinofuranosylcytosine (ara-C) on acute myeloblastic leukaemia (AML) cells. Br J Haematol 1988;70:121-3.
4. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:1272-8.
5. Tanaka M. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res 1993;17:585-92.
6. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989;3:328-34.
7. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 1991;78:2674-9.
8. Te Boekhorst PA, Löwenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994;8:1480-6.
9. Te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993;7:1191-8.
10. Inatomi Y, Toyama K, Clark SC, Shimizu K, Miyauchi J. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994;54:455-62.
11. Reuter C, Aufder Landwehr U, Schleyer U, et al. Modulation of intracellular metabolism in cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 1994;8:217-25.
12. Terpstra WE, Löwenberg B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997; 11:315-27.
13. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675-85.
14. Ohno R. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Res 1998;22:1143-54.
15. Rossi HA, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2002;16:310-5.
16. Frenette PS, Desforges JF, Schenkein DP, Rabson A, Slapack CA, Miller KB. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol 1995;49:48-55.
17. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79:2246-55.
18. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood 1994;83:2086-92.
19. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment ofacute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996;14:2150-9.
20. Löwenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-506.
21. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:2478-84.
22. Mitelman F, ed. ICSN 1995: an international system for human cytogenetic nomenclature (1995). Basel, Switzerland: Karger, 1995.
23. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
24. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69-79.
25. Löwenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:65-75.
26. Cannistra SA, DiCarlo J, Groshek P, et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991;5:230-8.
27. Baer MR, Bernstein SH, Brunetto VL, et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996;87:1484-94.
28. Löwenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-92.
29. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
30. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7.
31. Löwenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:2952-61.
32. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998;91:2722-30.